SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s ...
Spyre Therapeutics hit the key target in a trial of its candidate treatment for moderate to severely active ulcerative colitis. The clinical-stage biotechnology company said Monday it achieved ...
Findings showed 32% of patients achieved clinical remission (Mayo score ≤2 points, with no individual subscore >1) at week 6. The Food and Drug Administration (FDA) has expanded the approval of ...
Shares of Spyre Therapeutics jumped ahead of the opening bell after the biotechnology company hit the key target in a trial of its candidate treatment for moderate to severely active ulcerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results